MediciNova Set for Breakout with Key Clinical Trials Results
AI Prediction of MediciNova, Inc. (MNOV)
MediciNova, a biopharmaceutical company focused on neurological disorders and fibrotic diseases, shows potential for significant stock movement driven by key clinical trials results for its leading drug candidates, MN-166 and MN-001. These trials are expected to provide pivotal data that could significantly impact the stock price.
MNOV Report Information
Prediction Date2025-07-03
Close @ Prediction$1.25
Mkt Cap68m
IPO DateN/a
AI-derived Information
Recent News for MNOV
- Aug 19, 7:30 am — MNOV files 8-K with regulatory language (ScanScor Filing Bot)
- Aug 13, 5:46 pm — MediciNova: Q2 Earnings Snapshot (Associated Press)
- Jul 15, 8:00 am — MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients (GlobeNewswire RSS)
- Jun 30, 8:00 am — MediciNova CEO Provides Shareholder Update (GlobeNewswire RSS)
- Jun 8, 8:00 am — MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment (GlobeNewswire RSS)
- May 26, 7:00 pm — MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire RSS)
- May 14, 6:44 pm — MediciNova: Q1 Earnings Snapshot (Associated Press)
- Apr 27, 7:00 pm — New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation (GlobeNewswire)
- Mar 23, 9:44 am — Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls (The Fly)
- Mar 16, 7:00 am — MediciNova to Participate at the 38th Annual ROTH Conference (GlobeNewswire)
- Feb 20, 6:40 am — MediciNova: Q4 Earnings Snapshot (Associated Press Finance)
- Jan 29, 6:00 pm — MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.